Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MG Biologics is a veterinary biotechnology company specializing in the development and manufacture of antibody-based biologics for equine and bovine health. Based in Ames, Iowa, the company provides USDA-licensed hyperimmunized plasma, antitoxins, and antibody products designed to treat conditions such as Failure of Passive Transfer (FPT) and specific infectious diseases. Their portfolio includes specialized treatments for Rhodococcus equi, West Nile Virus, and Clostridial enterotoxemia. In addition to its commercial product line, MG Biologics offers custom antibody production and diagnostic services for veterinarians and animal owners. The company operates a USDA-licensed manufacturing facility to ensure high standards of safety and efficacy for its biological products.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MG Biologics.